William Blair Comments on Charles River Laboratories International, Inc.’s Q1 2025 Earnings (NYSE:CRL)

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities research analysts at William Blair dropped their Q1 2025 earnings estimates for shares of Charles River Laboratories International in a report issued on Thursday, August 8th. William Blair analyst M. Smock now expects that the medical research company will post earnings per share of $2.53 for the quarter, down from their prior estimate of $2.69. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.99 per share. William Blair also issued estimates for Charles River Laboratories International’s Q2 2025 earnings at $2.74 EPS.

Several other equities analysts also recently issued reports on CRL. Barclays cut their price target on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. TD Cowen cut their price target on shares of Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a report on Monday. Mizuho initiated coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They set a “neutral” rating and a $235.00 price target for the company. Evercore ISI cut their price target on shares of Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Finally, Robert W. Baird cut shares of Charles River Laboratories International from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $239.00 to $191.00 in a research report on Thursday, August 8th. Ten equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $231.00.

Charles River Laboratories International Trading Up 4.7 %

Shares of CRL stock opened at $203.49 on Monday. Charles River Laboratories International has a 12-month low of $161.65 and a 12-month high of $275.00. The company has a market capitalization of $10.48 billion, a P/E ratio of 23.94, a P/E/G ratio of 2.32 and a beta of 1.38. The firm has a 50-day moving average price of $214.58 and a 200 day moving average price of $231.16. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds and other institutional investors have recently bought and sold shares of CRL. Tortoise Investment Management LLC raised its position in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 57 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Charles River Laboratories International during the first quarter worth $41,000. VisionPoint Advisory Group LLC grew its stake in shares of Charles River Laboratories International by 45.1% during the fourth quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock worth $49,000 after purchasing an additional 65 shares during the period. Brown Brothers Harriman & Co. increased its holdings in Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 95 shares during the last quarter. Finally, Sunbelt Securities Inc. lifted its stake in Charles River Laboratories International by 1,072.7% in the first quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after buying an additional 236 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International declared that its board has initiated a stock buyback program on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).